	US 12,404,313 B2
	GDNF fusion polypeptides and methods of use thereof
Jasbir S. Seehra, Lexington, MA (US); and Jennifer Lachey, Lincoln, MA (US)
Assigned to Keros Therapeutics, Inc., Lexington, MA (US)
Filed by Keros Therapeutics, Inc., Lexington, MA (US)
Filed on Feb. 16, 2024, as Appl. No. 18/443,769.
Application 18/443,769 is a division of application No. 16/348,982, granted, now 11,912,750, previously published as PCT/US2017/060953, filed on Nov. 9, 2017.
Claims priority of provisional application 62/420,480, filed on Nov. 10, 2016.
Prior Publication US 2024/0209048 A1, Jun. 27, 2024
Int. Cl. C07K 14/475 (2006.01); A61K 38/00 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); A61P 25/00 (2006.01); C07K 14/47 (2006.01); C07K 14/765 (2006.01); C07K 14/78 (2006.01); C07K 19/00 (2006.01)

CPC C07K 14/4756 (2013.01) [A61P 3/04 (2018.01); A61P 3/10 (2018.01); A61P 25/00 (2018.01); C07K 14/4702 (2013.01); C07K 14/475 (2013.01); C07K 14/765 (2013.01); C07K 14/78 (2013.01); C07K 19/00 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01); C07K 2319/31 (2013.01)]

15 Claims

1. A method of treating and/or preventing a neurological disease in a subject, said method comprising administering to said subject a glial-derived neurotrophic factor (GDNF) fusion polypeptide consisting of the formula A-L-B, wherein

A is an Fc domain;

L is a linker; and

B has at least 95% sequence identity to a GDNF variant, wherein the sequence of the GDNF variant is (a) the sequence of amino acids 92-211 of SEQ ID NO: 1 or (b) a fragment of the sequence of amino acids 92-211 of SEQ ID NO: 1 comprising amino acids 118-211 of SEQ ID NO: 1.